Abstract
It is generally accepted that secondary malignancies, mainly leukemia, are iatrogenic diseases brought about by various anti-cancer treatment modalities such as chemotherapy with alkylating agents, topoisomerase II inhibitors or by radiotherapy (1-4). The exposure to these treatment modalities is associated with various chromosomal aberrations such as chromosomal breaks, gene rearrangements or translocations (5-7). Two of the most frequent genetic changes in secondary, drug induced leukemias are translocation breakpoints of the MLL (HRX) and the AML1 genes (8-9).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
